Identification of pyrazolopyridazinones as PDE delta inhibitors.Papke, B., Murarka, S., Vogel, H.A., Martin-Gago, P., Kovacevic, M., Truxius, D.C., Fansa, E.K., Ismail, S., Zimmermann, G., Heinelt, K., Schultz-Fademrecht, C., Al Saabi, A., Baumann, M., Nussbaumer, P., Wittinghofer, A., Waldmann, H., Bastiaens, P.I.
(2016) Nat Commun 7: 11360-11360
- PubMed: 27094677
- DOI: https://doi.org/10.1038/ncomms11360
- Primary Citation of Related Structures:
- PubMed Abstract:
The prenyl-binding protein PDEδ is crucial for the plasma membrane localization of prenylated Ras. Recently, we have reported that the small-molecule Deltarasin binds to the prenyl-binding pocket of PDEδ, and impairs Ras enrichment at the plasma membrane, thereby affecting the proliferation of KRas-dependent human pancreatic ductal adenocarcinoma cell lines. Here, using structure-based compound design, we have now identified pyrazolopyridazinones as a novel, unrelated chemotype that binds to the prenyl-binding pocket of PDEδ with high affinity, thereby displacing prenylated Ras proteins in cells. Our results show that the new PDEδ inhibitor, named Deltazinone 1, is highly selective, exhibits less unspecific cytotoxicity than the previously reported Deltarasin and demonstrates a high correlation with the phenotypic effect of PDEδ knockdown in a set of human pancreatic cancer cell lines.
Department of Chemical Biology, Max Planck Institute of Molecular Physiology, D-44227 Dortmund, Germany.